tbuckley/cabot-search huggingface dataset:
The outcome of end-stage renal disease patients on dialysis who undergo chemotherapy.
Authors: J. C. Velasco, J. Munoz, M. DeJesus, S. Soman, D. Wang
Journal: Journal of Clinical Oncology (2011)

e16593 Background: The presence of end-stage renal disease (ESRD) requiring dialysis in patients with malignancy is an ominous prognostic factor associated with decreased life expectancy. Lacks of clinical data provide guidance to the administration of chemotherapy in these patients since they have always been excluded from clinical trials. This retrospective study of cancer patients with ESRD is the first to review the tolerance of chemotherapy among these patients and its impact on their survival. Methods: Out of 1099 screened patients, 154 ESRD patients were identified with a new diagnosis of malignancy. The survival outcomes were analyzed based on the stage of malignancy and indication for chemotherapy as for non-ESRD patients. A log-rank test was used to compare the survival time in days between stratified subgroups of patients having received or not received chemotherapy. The mean number of chemotherapy cycles received was 2.7 from a mean of 4.6 planned for those patients who had received chemotherapy. Results: The median survival of this group of patients from their cancer diagnosis was 544 (CI 95%: 276, 675) days. Regardless the stage of malignancies, the median survival was longer for patients who did not receive chemotherapy (581 vs. 200 days, p=0.01). Chemotherapy was indicated for 85 of these patients and their median survival was much shorter than those where chemotherapy was not indicated (171 vs. 1363 days, p <0.001). Seventy-eight of chemotherapy-indicated patients were found with advanced (stage III and IV) malignancies, chemotherapy administration to these patients favored a slightly prolonged survival (187.5 vs. 96.5 days, p=0.596) though statistically not significant. This potential chemotherapy benefit was further demonstrated among the patients with stage IV cancer diagnosis (166 vs. 60 days, p=0.192). Conclusions: Administration of chemotherapy to cancer patients with ESRD may adversely impact survival. Chemotherapy to these patients with advanced malignancies may be tolerated and may deliver potential survival benefit with modification of regimens and coordination of dialysis schedule. Further prospective study of this patient population is warranted.
MA03.03 High Risk for Second Primary Lung Cancer in Taiwanese Early-Onset Female Breast Cancer Patients
Authors: Pei-Ying Lin, Ching-Yao Yang, Ching-Heng Lin, Tzu-Pin Lu, James Chih-Hsin Yang, Chong-Jen Yu, Kinwei Chan, Pan-Chyr Yang
Journal: Journal of Thoracic Oncology (2017)
Fetal microchimerism in breast and colon cancer.
Authors: M. Kamper-Jørgensen, R. J. Biggar, C. L. Stamper, H. Hjalgrim, A. Tjønneland, A. Olsen, A. N. Andersen, K. Rostgaard, N. Kroman, V. K. Gadi
Journal: Journal of Clinical Oncology (2011)

1574 Background: Cells acquired by a woman from her baby that durably persist in her blood and tissues is known as fetal microchimerism (FMc). In women with breast cancer, frequency and quantity of FMc in blood and breast tissue is reduced compared to healthy women. Whether the absence of fetal microchimerism predicts risk for developing breast cancer is unknown. FMc was evaluated in buffy coat cells from presumed healthy women who later developed breast cancer or colon cancer, a cancer in which prior pregnancy appears protective but has different associations with endocrine risk factors. Methods: Women studied were participants in the Danish Diet, Cancer and Health study. They were recruited from December 1993 to May 1997, aged 50-65 at the time of recruitment (interview, demographic and risk-factor questionnaire, and phlebotomy), and prospectively monitored for health outcomes including cancer. DNA from repository buffy coat specimens was tested for male FMc with quantitative PCR targeting the DYS14gene on the Y chromosome. For this analysis, 89 women who developed breast cancer and 67 women who developed colon cancer were evaluable for FMc. Results were compared to 272 women who remained cancer free. Results: Compared to cancer-free women, FMc was detected less frequently in breast cancer patients (40.5% vs. 69.9%, age-adjusted OR==0.38, 95%CI of 0.25-0.58). The inverse association of FMc with breast cancer was consistent across cancer specific factors (receptor status, primary size, nodal involvement, TNM stage, and histology). Compared to cancer-free women, FMc was positively associated with developing colon cancer (89.6%, age-adjusted OR==3.05, 95%CI of 1.39-6.69). There was both a trend of increasing frequency of FMc temporally closer to diagnosis, <4 years versus > 8years since phlebotomy (p==0.02) and of increasing concentrations of FMc (p<0.01) with developing colon cancer, but neither trend was detected for breast cancer (p==0.75 and 0.34, respectively). Conclusions: Women who fail to acquire or maintain detectable FMc in the blood are at higher risk of developing breast cancer. Surprisingly, women who develop colon cancer harbored FMc more frequently than cancer-free women. FMc is a risk factor unexplored in many cancers. Mechanistic studies are warranted.
Potent Synergistic Activity of the NAD+ Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.
Authors: Gabriele Zoppoli, Michele Cea, Floriana Fruscione, Santina Bruzzone, Debora Soncini, Davide Bedognetti, Eva Moran, Enrico Balleari, Andrea Bruzzone, Anna Garuti, Gabriella Cirmena, Ilaria Rocco, Marco Gobbi, Riccardo Ghio, Yves Pommier, Angelo Michele Carella, Alberto Ballestrero, Silvio Parodi, Franco Patrone, Alessio Nencioni
Journal: Blood (2009)
Trans-sigmoidal endoscopic ultrasonography-guided fine needle biopsy of a pancreas allograft for the diagnosis of post-transplant lymphoproliferative disorder
Authors: Hyungil Seo, Dong Cho, Sun-Ho Lee, Jin Shin, Young Kim, Do Park
Journal: Endoscopy (2017)

Biopsy of pancreas allografts has a critical role in the evaluation of pancreas allograft dysfunction [1]. However, percutaneous ultrasound or computed tomography (CT)-guided biopsy of a pancreas allograft in the pelvis may not be feasible in some cases. Pelvic lesions are easily imaged endosonographically from the rectum or distal sigmoid colon. Although transrectal endoscopic ultrasonography (EUS)-guided biopsy or drainage for pelvic lesions has been demonstrated to be feasible and safe [2] [3], there have been no reports of lower gastrointestinal EUS-guided fine needle biopsy (FNB) of a pancreas allograft in the pelvis owing to the unique anatomic configuration of the post-transplant anatomy [4].
P1.03-065 Comparison of the Proposed IASLC 8th TNM Lung Cancer Staging System to the 7th Edition
Authors: Joseph Hwang, Barbara Page, David Flynn, Linda Passmore, Elizabeth Mccaul, Ian Yang, Morgan Windsor, Rayleen Bowman, Rishendran Naidoo, Tracy Guan, Shoni Philott, Michael Blake, Kwun Fong
Journal: Journal of Thoracic Oncology (2017)
Cost Evaluation of Rituximab Plus MCP vs. MCP Alone in Advanced Stage Indolent Non-Hodgkin’s-Lymphoma Based on a Randomized Controlled Multicenter Trial.
Authors: Klaus Hieke, Rita Pasold, Sabine Neser, Dietger Niederwieser, Andreas Neubauer, Gottfried Doelken, Ralph Naumann, Thomas Fietz, Mathias Freund, Robert Rohrberg, Klaus Hoeffken, Astrid Franke, Thomas-Hein Ittel, Erika Kettner, Ursula Haak, Ullrich Mey, Christian Klinkenstein, M. Assmann, Ullrich von Gruenhagen, Klaus Dachselt, Helga Schwenke, Dorothee Bleyl, Heiner Wolf, Sabine Hahnfels, Franz-Adolph Hoffmann, Volker Lakner, Peter Richter, Detlev Haehling, H.H. Wolf, H. Eschenburg, N. Grobe, M.-R. Clemens, Michael Herold
Journal: Blood (2004)
P2.02-055 Pathologic Mediastinal Nodal and Metabolic Tumor Response to Predict Overall Survival in Stage IIIA-N2 NSCLC after Neoadjuvant Chemotherapy
Authors: Christophe Dooms, Charlotte Van De Kerkhove, Paul De Leyn, Eric Verbeken, Karin Pat, Sigrid Stroobanst, Ingel Demedts, Sofie Derijcke, Herbert Decaluwe, Johan Vansteenkiste, Christophe Deroose
Journal: Journal of Thoracic Oncology (2017)
A multicenter analysis of the predictors of fertility preservation in women with breast cancer: Role of neoadjuvant chemotherapy.
Authors: J. Kim, K. Oktay, C. Gracia, S. Lee, C. Morse, J. Mersereau
Journal: Journal of Clinical Oncology (2011)

9118 Background: Increasing survival rates after breast cancer have heightened importance of fertility preservation treatment (FP) (embryo, oocyte, or ovarian tissue cryopreservation). Many factors can influence a patient’s decision to pursue FP. We evaluated predictors of undergoing FP in women with breast cancer. Methods: Retrospective cohort study of 223 patients with breast cancer undergoing FP counseling at three academic fertility preservation centers in 2005-2010. Results: Women in Center-1 had a significantly lower FP rate compared to Centers-2 and -3 (27.0%, 73.0%, and 52.6% respectively, p < 0.001). Compared to Centers-2 and -3, patients at Center-1 had significantly higher body mass index (BMI), more advanced cancer stage, and lower income. The rates of hormone receptor positivity and neoadjuvant chemotherapy (NAC) were significantly higher in Center-1. Overall, women who had FP were older, more underweight, wealthier, and had lower cancer stage compared to women who did not have FP. The rate of NAC was significantly lower in women who underwent FP. After adjusting for age, BMI, income, and cancer stage, a negative correlation persisted between NAC and FP (OR= 0.17, 95% CI 0.03-0.88). Conclusions: While age, BMI, income, cancer stage, and NAC appear to predict the likelihood of undergoing FP, NAC is the only modifiable variable. While NAC is recommended in women with advanced breast cancer, it has broader use under research protocols in Center-1. NAC restricts the time available for FP. Except in cases where NAC clearly improves survival, oncologists may consider offering adjuvant chemotherapy, rather than NAC, in women who are interested in FP. Characteristics of women based on FP. FP (+) FP (-) P value n=139 n=84 Age (years) 37.7 35.5 0.006 BMI (kg/m2) 23 25.3 0.006 Parity 0.2 0.3 0.15 Income (USD/year) 148,634.7 98,478.6 0.004 Days from diagnosis to consult 58.4 46.1 0.27 Stage (%) I-II 97.2 83.3 0.001 III 2.8 16.7 NAC (%) Yes 3.3 29 <0.001 No 96.7 71
P158 Fluticasone furoate(FF)/vilanterol (VI) once daily improves night-time awakenings in asthma
Authors: N Barnes, L Yates, MR Gibbs, R Forth
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> FF/VI, the first once daily inhaled corticosteroid/long-acting ß2-agonist combination available for the treatment of asthma, has demonstrated a sustained 24 hour improvement in lung function and improvement in symptom-free 24 hour periods. <h3>Methods</h3> Post-hoc analyses of diary card data from three Phase III studies were performed to examine whether there was an improvement in night-time awakening during the studies for those patients treated with the addition of vilanterol to fluticasone furoate. The diary card scale used is described below. Changes in night-time awakenings over the duration of the studies were analysed for percentage of patients with ≥50% symptom-free nights, including the time taken for 50% of patients to achieve 7 nights without symptoms. Night-time Symptom Score: 0 = No symptoms during the night 1 = Symptoms causing me to wake once (or wake early) 2 = Symptoms causing me to wake twice or more (including waking early) 3 = Symptoms causing me to be awake for most of the night 4 = Symptoms so severe that I did not sleep at all To be counted as symptom-free during the night the patient needed to record a score of 0. <h3>Results</h3> The percentage of patients with ≥50% symptom-free nights was generally higher in patients treated with FF/VI compared to either FF or FP alone (Table below). The time (in days) for 50% of patients to achieve 7 nights without symptoms was achieved sooner with patients treated with FF/VI compared to FF alone (Table). <h3>Conclusions</h3> In general, night-time awakenings improved over time in asthma patients with FF/VI and improved faster with FF/VI compared with FF or placebo.
P3.02b-009 Plasma and Tissue Inflammatory and Angiogenic Biomarkers to Explore Resistance to EGFR-TKIs and Association with VeriStrat Status
Authors: Elena Brioschi, Francesca Corti, Chiara Lazzari, Silvia Foti, Olga Nigro, Angelo Corti, Claudio Doglioni, Luisella Righi, Alessandra Bulotta, Mariagrazia Viganò, Monica Ducceschi, Valter Torri, Luca Porcu, Fred R. Hirsch, Heinrich Roder, Silvia Novello, Luca Gianni, Vanesa Gregorc
Journal: Journal of Thoracic Oncology (2017)
Researchers aim to grow replacement bone for people injured by landmines
Authors: Ingrid Torjesen
Journal: BMJ (2017)

Emilio Morenatti/PA

University of Glasgow researchers are using 3D print technology to synthetically grow bespoke bone as part of a project to increase the amount of tissue that can be conserved during reconstructive surgery for landmine injuries.

An estimated 4300 people are injured or killed by landmines every year, such as this boy, Mohammad Mahdi, who lost his foot in a mine explosion in Afghanistan. …
OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012
Authors: Scott Gettinger, Naiyer Rizvi, Laura Chow, Hossein Borghaei, Julie Brahmer, Frances Shepherd, Neal Ready, David Gerber, Scott Antonia, Jonathan W. Goldman, Rosalyn Juergens, William Geese, Tina Young, Xuemei Li, Matthew Hellmann
Journal: Journal of Thoracic Oncology (2017)
Knockdown of CCR7 or Its Ligands Causes a Loss of Central Nervous System Involvement in Notch1 Induced T-ALL
Authors: Silvia Buonamici, Thomas Trimarchi, Apostolos Klinakis, Linsey Reavie, Brenton G. Mar, Eric Gehrie, Emma L. Kuan, Gwendalyn J. Randolph, Jonathan Bromberg, Iannis Aifantis
Journal: Blood (2008)
Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML
Authors: Jean-Pierre Issa, Ryan Castoro, Farhad Ravandi-Kashani, Stefan Faderl, Xuelin Huang, Elihu Estey, Gautam Borthakur, Gail Morris, Guillermo Garcia-Manero, Hagop M Kantarjian
Journal: Blood (2008)
P2.02-025 Continuous Intravenous Pumping Endostar Combined with Radiochemotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer
Authors: Hong Lian Ma, Zhou Guang Hui, Lu Jun Zhao, Yu Jin Xu, Yi Rui Zhai, Run Ye Wu, Qing Song Pang, Guang Yin Zhu, Dong Ming Li, Yu Tang, Jun Liang, Yup Kong, Ming Chen, Lv Hua Wang
Journal: Journal of Thoracic Oncology (2017)
Obama calls plan to repeal Affordable Care Act “reckless” and “irresponsible”
Authors: Michael McCarthy
Journal: BMJ (2017)

Republican plans to repeal the 2010 Affordable Care Act (ACA) without passing a law to replace it are “reckless” and “irresponsible,” the outgoing president, Barack Obama, said in a commentary published in the New England Journal of Medicine .1

Republican leaders in Congress have said that they will move quickly to repeal the act but have acknowledged that they will probably leave many of the law’s provisions intact for several years to allow time to draft a replacement—a strategy called “repeal first and replace later.”

In his article, Obama warned that repealing the law without replacement would leave the healthcare system “standing on the edge of a …
MicroRNA-222 to enhance invasion and migration through MST3 in colorectal cancer and to predict for CRC patients progression.
Authors: Heli Gao, Chunmei Bai, Zhao Sun
Journal: Journal of Clinical Oncology (2015)

e22006 Background: The aberrant expression of microRNAs has been demonstrated to play a crucial role in the initiation and progression of colorectal cancer (CRC). miR-222 is overexpressed in many tumors and activates cell cycle process by series of target genes, while the role of miR-222 in CRC is still unclear. Methods: The expression level of miR-222 in CRC patients tissues were evaluated by RT-PCR. Cell proliferation and the migration/invasion assay were analyzed by MTS and Transwell assays. Cell cycle distribution and apoptosis were assessed by flow cytometry. Dual luciferase reporter assay was used to identify the target of miR-222. Results: The expression level of miR-222 was higher in tumor tissues of CRC patients than in pericarcinous tissues. And the patients with high D-value of miR-222 expression in tumor tissue and matched pericarcinous tissue were easier to recurrent. Inhibition of miR-222 didn't influence the proliferation, cell cycle or apoptosis of CRC cells in vitro. While decreasing miR-222 level effectively reduced migration and invasion of CRC cell lines. Bioinformatics and luciferase reporter assay revealed that miR-222 specifically targeted the 3'-UTR of Melanoma inhibitory activity member 3 (MIA3) and Mammalian sterile 20-like kinase 3 (MST3). Overexpression of miR-222 decreased the expression lever of both MST3 and MIA3. Either Down-regulation of MIA3 or MST3 enhanced the migration and invasion of CRC cell lines. MST3 expression level was lower in CRC than in pericarcinous tissue. Conclusions: Our study revealed two new target gene of miR-222, MIA3 and MST3. And miR-222 enhances migration and invasion in CRC cells probably by down-regulation MST3 and MIA3. miR-222 is overexpressed in CRC tumor tissues andMST3 expression level is low in Chinese CRC patients. The expression of miR-222 and MST3 is a valuable prognostic indicator for CRC patients.
Leading MPs urge prime minister to start talks on health and social care funding
Authors: Gareth Iacobucci
Journal: BMJ (2017)

Leading MPs have urged Theresa May to invite all political parties to discussions in a bid to reach a cross party agreement on the future of healthcare and social care funding.

In a letter published on 6 January Sarah Wollaston, chair of the House of Commons Health Committee, Meg Hillier, chair of the Public Accounts Committee, and Clive Betts, chair of the Communities and Local Government Committee, said that a “political consensus” was needed to tackle the huge challenges facing social care and the NHS.1

The MPs called on the prime minister to invite …
P1.01-036 Lung Cancer Screening Program Is Cost Effective in French Setting: A Model Based Study
Authors: Christos Chouaid, Juliette Vella-Boucaud, Jean Claude Pairon, Anne Duburcq, Bruno Detournay, Laurent Boyer, Bruno Housset, Pascal Andujar, Isabelle Monnet
Journal: Journal of Thoracic Oncology (2017)
OA06.02 Mutational Load Predicts Survival in LDCT Screening-Detected Lung Cancers
Authors: Gabriella Sozzi, Carla Verri, Cristina Borzi, Todd Holscher, Matteo Dugo, Andrea Devecchi, Katherine Drake, Stefano Sestini, Paola Suatoni, Elisa Romeo, Mattia Boeri, Ugo Pastorino
Journal: Journal of Thoracic Oncology (2017)
P144 Specialist domiciliary pharmacy intervention may reduce exacerbation frequency and hospitalisation in patients with severe chronic obstructive pulmonary disease
Authors: V Hunt, D Anderson, R Lowrie
Journal: Thorax (2016)

COPD is the 3<sup>rd</sup> most common cause for hospital admission in the UK. Patients with COPD are often unable to attend specialist clinics, when factors contributing to exacerbations can be treated, due to the unstable nature of the condition and the degree of breathlessness experienced. There is also a high level of polypharmacy in this population. Domiciliary specialist pharmacy intervention may help identify and treat these issues. <h3>Hypothesis</h3> Specialist Domiciliary Pharmacy intervention reduces exacerbation frequency and hospitalisation in patients with Severe COPD Patients who were referred to a specialist COPD clinic between March 2015 and January 2016 were assessed. Those with polypharmacy and high exacerbation frequency or severe breathlessness (MRC grade 4–5) were identified and offered domiciliary pharmacy review. Patients who consented were visited at home with a comprehensive review of medication, the case was then discussed at an MDT level and therapeutic changes implemented. A comparator group of matched patient were identified and followed up without pharmacy intervention. Baseline data were collected including demographics, smoking status, FEV<sub>1</sub>, MRC Grade, hospitalisation rates, exacerbation frequency and current medications. Patient records were then reviewed after a 6 month period to look at impact of intervention on hospitalisation, exacerbation frequency, antibiotic and steroid prescription in the two groups. <h3>Results</h3> A total of 88 patients received intervention and 87 patients were followed up in a comparator group. Patients were matched in terms of sex, BMI, socioeconomic deprivation, smoking status, FEV<sub>1</sub>, MRC Grade, LTOT use and hospitalisation frequency. Patients had an average of 3.5 visits with an average of 7.6 interventions per patient, therapeutic changes being the most frequent. Review after 6 months of intervention demonstrated that the intervention group had a significant reduction in hospitalisation (p &lt; 0.01) and exacerbation frequency (p &lt; 0.01) (Figure 1) along with antibiotic and steroid use in comparison to the comparator group. This project was a service evaluation rather than a double blinded, randomised control study. The results however suggest that specialist pharmacy intervention in a setting appropriate for a disabled population has a positive impact on exacerbation frequency and hospitalisation.
P2.03a-007 Pem/CBP/Bev Followed by Pem/Bev in Hispanic Patients with NSCLC: Outcomes According to Combined Score of TS, ERCC1 and VEGF Expression
Authors: Andrés Cardona, Leonardo Rojas, Beatriz Wills, Oscar Arrieta, Hernan Carranza, Carlos Vargas, Jorge Otero, Mauricio Cuello, Luis Corrales, Claudio Martin, Carlos Ortiz, Sandra Franco, Rafael Rosell
Journal: Journal of Thoracic Oncology (2017)
Long-term Posterior Capsule Opacification Reduction with Square-Edge Polymethylmethacrylate Intraocular Lens
Authors: Aravind Haripriya, David F. Chang, Balakrishnan Vijayakumar, Agrawal Niraj, Madhu Shekhar, Singh Tanpreet, Srinivasan Aravind
Journal: Ophthalmology (2017)
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer
Authors: Emil Christensen, Karin Birkenkamp-Demtröder, Iver Nordentoft, Søren Høyer, Kirstin van der Keur, Kim van Kessel, Ellen Zwarthoff, Mads Agerbæk, Torben Falck Ørntoft, Jørgen Bjerggaard Jensen, Lars Dyrskjøt
Journal: European Urology (2017)
Sex Bias—Beyond Pay Inequity
Authors: Pamela W. Duncan
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
90Y-Zevalin® (90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation of FCM Induction Chemotherapy in Mantle Cell Lymphoma (MCL) Patients: Results from the PLRG upon Completed Enrollment.
Authors: Wojciech Jurczak, A. Giza, M. Szostek, A. Hubalewska-Dydejczyk, A. Sowa-Staszczak, W. Knopinska-Posluszny, A. Hellmann, B. Zdziarska, T. Wrobel, S. Krycz-Krzemien, L. Poplawska, I. Federowicz, Jan Walewski, Aleksander Skotnicki
Journal: Blood (2006)